Greg Slabodkin is a healthcare journalist with a focus on health equity, mental health, behavioral health, and addiction. As a writer for CIO Dive and BioSpace, his articles cover a range of topics in the healthcare industry, including gene editing, drug approvals, industry trends, and the intersection of politics and healthcare. His work has also been featured in Med Tech News and The Science Advisory Board.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Greg Slabodkin's focus is on the healthcare and pharmaceutical industry, specifically covering topics related to life sciences, biopharma, FDA approvals, gene therapy, CRISPR technology, weight-loss drugs, earnings reports from relevant companies in the sector as well as mergers and acquisitions. His articles often cite data and government announcements.
Pitching ideas related to new drug launches or breakthroughs in gene therapy or regenerative medicine would likely resonate with Greg. He also covers how political decisions impact this sector so insights into the intersection of public policy and healthcare could be valuable for his coverage. Given that he cites a significant amount of data in his articles it may be beneficial to provide him with access to proprietary research or exclusive statistics within these areas of interest.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Heather-Mckenzie
J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio's Skysona comes at a bad time for the company; Sen. Warren calls for scrutiny of Novo's purchase of Catalent; and other news.
This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street's expectations. Pfizer is projected to have a strong quarter, while Eli Lilly could pull ahead of Novo Nordisk in the obesity space. Moderna, by contrast, has a decidedly negative outlook.
By: Heather Mckenzie, Greg Slabodkin, Jef Akst, Annalee Armstrong
Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million in radiopharma while selling its consumer health unit; Novo Nordisk’s positive Rybelsus results in cardiovascular disease; and more.
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the company's leadership. However, analysts are supportive of the embattled executive.
While some analysts say Donald Trump is a wild card when it comes to drug pricing, many argue his presidency would be more positive for the industry overall, as Kamala Harris has her price-cutting sights squarely on Big Pharma.
By: Greg Slabodkin
CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer reported that third-quarter revenue and adjusted profit beat the analysts' consensus.
> Listen on Spotify > Listen on Apple Podcasts > Listen on Amazon Music > Listen on iHeart
By: Greg Slabodkin
Lilly CEO Dave Ricks in Wednesday's third-quarter earnings call acknowledged that the company is at the mercy of wholesaler stocking decisions.
By: Greg Slabodkin, Heather Mckenzie, Jef Akst, Annalee Armstrong
In our anniversary episode, we discuss a rare earnings miss for Eli Lilly, a pivotal metabolic dysfunction–associated steatohepatitis victory for Novo Nordisk’s Wegovy, growing excitement about CAR Ts for autoimmune disease and the ongoing controversy over HeLa cells.
With Novo Holdings' $16.5 billion buyout of Catalent being reviewed by regulators, what work the contract drug manufacturer may or may not be performing for Eli Lilly remains a point of contention.
(833) 317-6278 
